Hosted on MSN1mon
SCG’s HBV T-cell therapy shows promise in Phase I trial
SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T-cell receptor-engineered T Cell (TCR-T) therapy, SCG101. The therapy ...
Yahoo Finance28d
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight
Key TCR therapy companies such as Immunocore, Guangdong Xiangxue Precision Medical Technology Co., Ltd, Neogene Therapeutics, TScan Therapeutics, SCG Cell Therapy, Triumvira, JW Therapeutics ...
Yahoo Finance28d
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight
Key TCR therapy companies such as Immunocore, Guangdong Xiangxue Precision Medical Technology Co., Ltd, Neogene Therapeutics, TScan Therapeutics, SCG Cell Therapy, Triumvira, JW Therapeutics, Immatics ...